Bajaj Healthcare Ltd (BSE: 539872) is a Thane, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,144 Cr, it ranks #1,516 by market cap among the 6,137 Indian listed companies on FinBizNet, and #47 of 86 in Medicinal Chemicals and Botanical Products. At ₹312.60 (as of 25 Oct 2026), the share price is 36.1% below its 52-week high of ₹488.90 and 14.8% above its 52-week low of ₹272.35. The share price is down 34.8% over one year and down 3.3% over three months.
| Current Price | ₹312.60 |
|---|---|
| Market Cap | ₹1,144 Cr |
| BSE Code | 539872 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 50.3 |
| Return on Equity | 4.27% |
| Return on Assets | 5.51% |
| 52-Week Range | ₹272.35 – ₹488.90 |
| 1-Year Price Change | -34.8% |
| 3-Month Price Change | -3.3% |
| Beta (1Y) | 0.39 |
| Dividend Yield | 0.44% |
| Headquarters | Thane, Maharashtra |
| Website | www.bajajhealth.com |
| Revenue | ₹166 Cr |
|---|---|
| Net Profit | ₹14 Cr |
| Net Margin | 8.4% |
| EPS (Basic) | ₹4.13 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl x
1. Pharma-This segment engages in the API and formulation business. 2. Bulk Drugs-This segment manufactures and sells bulk drugs. 3. Formulations-This segment manufactures and markets active pharmaceutical ingredients, intermediates, and finished dosage formulations with focus on vitamins, amino acids, anti-convulsants, and finished dosage forms catering various therapeutic applications. 4. Intersegment Revenue-0
1. Development, Manufacturing and Marketing of Active Pharmaceutical Ingredients-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Bajaj Healthcare Ltd | ₹1,144 Cr | 50.3 | 4.27% | ₹166 Cr | -34.8% |
Listed by market capitalisation. Ratios are shown for context only.
Bajaj Healthcare Ltd is trading at ₹312.60, with a market capitalisation of ₹1,144 Cr.
Bajaj Healthcare Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Bajaj Healthcare Ltd has a P/E of 50.3 and a return on equity of 4.27%.
Bajaj Healthcare Ltd is listed on the BSE under the scrip code 539872.
Bajaj Healthcare Ltd's share price is down 34.8% over one year and down 3.3% over three months. Its 52-week range is ₹272.35 to ₹488.90.
In Q1 FY27, Bajaj Healthcare Ltd reported revenue of ₹166 Cr and net profit of ₹14 Cr, with basic EPS of ₹4.13 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.